Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

Published on April 8, 2013 at 12:50 AM · No Comments

Data from Berg's Proprietary Interrogative Biology™ Platform presented at the AACR Annual Meeting 2013

Berg - a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach - announced today that it will be presenting four abstracts at the AACR Annual Meeting 2013, in Washington, D.C. These data reveal key insights about cancer-cell metabolism and add to the growing body of evidence supporting the potential of Berg's proprietary Interrogative Biology™ Platform, which combines sophisticated analytics and integrated data models to understand human health and provide a broader view on diseases processes.

"These new findings provide further details into the metabolic machinery of cancer, allowing us to identify novel biomarkers and potential treatment targets," said Niven R. Narain , President, Co-Founder & Chief Technology Officer of Berg. "At Berg, we are working to understand human health more broadly and uncover solutions for diseases by mapping the first full picture of the human biology ecosystem, rather than individual disease triggers. We believe this approach has great potential to advance the treatment of cancer and other diseases."

"We are in the midst of a paradigm shift in the way we approach treating complex diseases like cancer," said Eric E. Schadt , PhD, Director of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai. "Berg is heralding this shift by challenging the mold of the current scientific process and evaluating the interconnectedness of the human system, rather than singular targets."

The data from Berg being presented at the AACR Annual Meeting 2013 include the following:

  1. Berg Interrogative Biology™ platform unravels novel biomarkers FLNB and LY9 in combination with PSA enhances specificity in serum of patients with prostate cancer. Sarangarajan, R., et. al.
    Poster Session: Apr 07, 2013, 1:00 PM - 5:00 PM,
    Location: Hall A-C, Poster Section 1, Abstract #7, Poster Board #7
  2. Mitochondrial priming of apoptotic machinery in pancreatic cancer by BPM 31510 to enhance efficacy of chemotherapy.
    Narain, N.R., et. al.
    Poster Session: Apr 08, 2013, 1:00 PM - 5:00 PM
    Location: Hall A-C, Poster Section 25, Abstract #1736, Poster Board #27
  3. Berg Interrogative Biology™ Informatics Suite: data driven integration of multi-omic technologies using Bayesian AI.  Rodrigues, L., et. al.
    Time/Date: Wednesday, Apr 10, 2013, 8:00 AM -12:00 PM
    Location: Hall A-C, Poster Section 26, Abstract # 5230, Poster Board #18
  4. Identification of Enolase1 as key drug target in breast cancer by the Berg Interrogative Biology™ platform. Jing, E., et. al.
    Time/Date: Wednesday, Apr 10, 2013, 8:00 AM -12:00 PM
    Location: Hall A-C, Poster Section 38, Abstract # 5542, Poster Board #22
Source:

Berg

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
TGen to lead first-in-patient clinical trial studies to test novel drugs for glioblastoma